Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Pre-Tax Margin

Income before tax as a percentage of revenue.

Incyte CorporationNASDAQ: INCY

Pre-Tax Margin · Q2 FY2026 · quarter ended Jun 2026

Pre-tax margin narrows to 44.9%

Pre-tax margin was 44.9% in Q2 FY2026, down 1.0 pp from a year earlier. On a trailing-twelve-month basis it was 33.8%, up 6.3 pp year over year. Over 3 fiscal years it widened by 16.8 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
44.9%+17.9 pp QoQ
Last fiscal yearDec 2025
32.4%+24.9 pp YoY
LTMJun 2026
33.8%+6.3 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.0 pp——
1 year+24.9 pp——
3 years+16.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
32.4%
Year-over-year change
+24.9pp

Pre-Tax Margin vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 pre-tax margin of 33.8% is the 4th highest of the 8 companies compared; the peer median is 33.3%.
  • Its year-over-year change of +6.3 pp is the 6th highest of 7, against a peer median of +76.9 pp.
  • Over three fiscal years its change of +16.8 pp compares with a peer median of +40.9 pp.
INCY Competitors Peer median
Pre-Tax Margin for INCY and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202681.9% +126.9 pp+40.9 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202643.9% +335.5 pp+152.9 pp
EXELExelixis, Inc.LTM Jul 202642.5% +7.7 pp+26.0 pp
INCYIncyte CorporationLTM Jun 202633.8% +6.3 pp+16.8 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202633.3% -1.0 pp-3.4 pp
GMABGenmab A/SLTM Jun 202621.9% —-15.5 pp
LEGNLegend Biotech CorporationLTM Sep 20262.4% +26.8 pp+353.5 pp
VSTMVerastem, Inc.LTM Mar 2026-391.2% +1095.8 pp+2165.7 pp
SLSSELLAS Life Sciences Group, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
Peer median (excluding INCY) 33.3%+76.9 pp+40.9 pp

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.99B3.39B3.7B4.24B5.14B
Cost of Revenue150.99M207M254.99M312.1M372.1M
Gross Profit2.84B3.19B3.44B3.93B4.77B
Gross Margin94.9%93.9%93.1%92.6%92.8%
Research & Development1.46B1.59B1.63B2.61B2.05B
Selling, General & Admin739.56M1B1.16B1.22B1.38B
Operating Expenses2.25B2.6B2.79B3.83B3.43B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
EBITDA630.2M599.64M919.43M408.16M1.76B
EBITDA Margin21.1%17.7%24.9%9.6%34.2%
Operating Income585.78M591.63M655.36M101.29M1.34B
Operating Margin19.6%17.4%17.7%2.4%26.1%
Interest Income000128.71M105.6M
Interest Expense1.91M2.67M2.55M2.28M2.43M
Other Income / Expenses(15.33M)(62.51M)178.86M215.34M321.66M
Income Before Tax570.44M529.12M834.22M316.63M1.66B
Pre-Tax Margin19.1%15.6%22.6%7.5%32.4%
Income Tax Expense(378.14M)188.46M236.62M284.02M377.8M
Net Income948.58M340.66M597.6M32.62M1.29B
Net Margin31.8%10.0%16.2%0.8%25.0%
EPS (Basic)4.301.532.670.166.59
EPS (Diluted)4.271.522.650.156.41
Weighted Avg Shares220.43M222M223.63M207.11M195.2M
Weighted Avg Shares (Diluted)222.07M223.96M225.93M210.53M200.7M

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.